期刊
NEUROSCIENCE LETTERS
卷 563, 期 -, 页码 51-54出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2014.01.004
关键词
Alzheimer's disease; CD33; PBMCs; Expression; Biomarker
资金
- National Natural Science Foundation of China [81000544, 81171209, 81371406]
- Shandong Provincial Natural Science Foundation, China [ZR2010HQ004, ZR2011HZ001]
- Medicine and Health Science Technology Development Project of Shandong Province [2011WSA02018, 2011WSA02020]
- Shandong Provincial Outstanding Medical Academic Professional Program
Recently, two independent genome-wide association studies (GWAS) have identified CD33 gene, encoding cluster of differentiation 33 (CD33), as a genetic locus associated with Alzheimer's disease (AD). It has been suggested that CD33 may contribute to AD pathogenesis by involving in inflammatory response, synaptic dysfunction and cell membrane processes. We analyzed the expressions of CD33 in peripheral blood mononuclear cells (PBMCs) in AD group and control group by real-time quantitative polymerase chain reaction and flow cytometry. Expression of CD33 mRNA was down-regulated in AD patients comparing to controls (p = 0.001). The frequency of CD33 positive monocytes was also lower in AD patients than in controls (44.02 +/- 22.17% versus 54.06 +/- 21.86%, p = 0.001). Moreover, we observed a correlation between CD33 positive monocytes levels and Mini Mental State Examination (MMSE) score (r = 0.220, p < 0.05). According to receiver operating characteristic (ROC) curve analysis, the diagnostic accuracy for CD33 alone is relatively lower, while, combining with additional parameters might further improve the diagnostic value for AD. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据